Cases & Deals

Junshi and Revitope team up for TEAC molecules through development, license, and equity

Clients Shanghai Junshi Biosciences Co., Ltd.

Jones Day represented Shanghai Junshi Biosciences Co., Ltd. in a research collaboration and license agreement with Revitope Oncology Inc. and its subsidiary to collaborate in the research and development of T-cell engaging cancer immunotherapies that utilize Junshi's antibody technology platform with Revitope's proprietary dual-antigen targeting technology platform. Junshi will designate up to 5 T-cell immunotherapeutic molecules. Revitope will receive a combination of development and commercialization milestones and tiered royalties on net sales. In addition, Junshi committed an equity investment into Revitope for up to 9.99% of its shares on an as-converted basis.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.